Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene, 18: 2241-2251, 1999.DeVore RF,Fehrenbacher L,Herbst RS,et al.A randomized phase Ⅱ trial comparing Rhumab VEGF ( recombinant humanized monoclonal antibody to ...
An efficient approach is to inhibit the proangiogenic activity of the vascular endothelial growth factor (VEGF), which can be done by means of Bevacizumab/rhuMab, a humanized anti-VEGF monoclonal antibody. However, upon VEGF inactivation... LA Mcphatter,ZN Rabbani,P Sonveaux,... - 《Cancer Re...
In vitro studyTrastuzumab (anti-HER2) exerts specific antitumor activity in tumor cells overexpressing HER2. Trastuzumab binds to the near-membrane region of HER2, and once bound to the receptor, this antibody down-regulates HER2 expression. Trastuzumab selectively inhibits ligand-independent HER2-HER3...
RhumAb Recombinant Humanized Anti-HER-2 Monoclonal Antibodydoi:10.1007/978-3-662-46875-3_102016
Allison DE, Gourlay SG, Koren E, Miller RM, Fox JA. Pharmacokinetics of rhuMAb CD18, a recombinant humanised monoclonal antibody fragment to CD18, in normal healthy human volunteers. BioDrugs. 2002; 16 :63–70.Allison DE, Gourlay SG, Koren E, Miller RM, Fox JA. 2002. Pharmacokinetics...
Treatment of cancer with the recombinant humanized monoclonal anti-erbb2 antibody 2C4 (rhuMAb 2C4)Tumors are identified as responsive to treatment with anti-HER2 antibodies by detecting the presence of a HER2/HER3 and/or HER2/HER1 protein complex or for HER2 phosphorylation in a sample of ...
(2000). A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus 5-fluorouracil/leucovorin (FU/LV) to FU/LV alone in patients with metastatic colorectal cancer. Proceedings of the American Society of Clinical ...
245 - 251 Phase I study of anti-IgE recombinant humanized monoclonal antibody rhuMAB-E25 (E25) in adults with moderate to severe asthma - EM|consultedoi:10.1016/S0091-6749(96)80469-6Jonathan CorrenJuergen FroehlichMonika SchoenhoffSheldon Spector...
Investigates the kinetics and thermodynamics of recombinant human monoclonal antibody rhuMAb vascular endothelial growth factor (VEGF) monomer. Determination of the rate constant of dimer formation; Negative change in entropy for dissociation; Occurrence of rhuMAb VEGF dimerization through hydrophobic ...
(2000). A phase II trial of single-agent rhumab VEGF (recombinant human- ized monoclonal antibody to vascular endothelial cell growth factor) in patients with relapsed metastatic breast cancer. Proc. Am. Soc. Clin. Onc. 19, A5.Sledge G, Miller K, Novotny W, et ...